Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics, i.e., colistin, tobramycin, aztreonam lysine and levofloxacin, are used as maintenance treatment for CF patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Taccetti, Giovanni, Francalanci, Michela, Pizzamiglio, Giovanna, Messore, Barbara, Carnovale, Vincenzo, Cimino, Giuseppe, Cipolli, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004710/
https://www.ncbi.nlm.nih.gov/pubmed/33810116
http://dx.doi.org/10.3390/antibiotics10030338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004710/
https://www.ncbi.nlm.nih.gov/pubmed/33810116
http://dx.doi.org/10.3390/antibiotics10030338

Ejemplares similares